August 17, 2017 3:23 PM ET

Biotechnology

Company Overview of Eagle Pharmaceuticals, Inc.

Company Overview

Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates includes include EP-4104, a dantrolene sodium for exertional heat stroke; EGL-4104-C-1702, dantrolene sodium for drug induced hypertherm...

50 Tice Boulevard

Suite 315

Woodcliff Lake, NJ 07677

United States

Founded in 2007

77 Employees

Phone:

201-326-5300

Key Executives for Eagle Pharmaceuticals, Inc.

Chief Executive Officer and Director
Age: 57
Total Annual Compensation: $1.8M
Chief Medical Officer and Executive Vice President
Age: 56
Total Annual Compensation: $1.2M
Chief Scientific Officer and Executive Vice President
Age: 58
Total Annual Compensation: $616.0K
Compensation as of Fiscal Year 2016.

Eagle Pharmaceuticals, Inc. Key Developments

Eagle Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2017

Eagle Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the six months ended June 30, 2017. For the quarter, the company reported total revenue of $50,108,000 against $40,918,000 a year ago. Income from operations was $5,902,000 against $13,656,000 a year ago. Income before income tax provision was $5,876,000 against $13,683,000 a year ago. Net income was $4,503,000 or $0.28 per diluted share against $13,099,000 or $0.80 per diluted share a year ago. Adjusted Non-GAAP net income was $7,910,000 or $0.49 per diluted share against $15,940,000 or $0.97 per diluted share a year ago. Adjusted Non-GAAP EBITDA was $10,968,000 against $16,624,000 a year ago. For the six months, the company reported total revenue of $126,901,000 against $70,508,000 a year ago. Income from operations was $38,598,000 against $12,758,000 a year ago. Income before income tax provision was $38,548,000 against $12,805,000 a year ago. Net income was $27,427,000 or $1.70 per diluted share against $12,202,000 or $0.74 per diluted share a year ago. Adjusted Non-GAAP net income was $34,528,000 or $2.14 per diluted share against $16,481,000 or $1.00 per diluted share a year ago. Adjusted Non-GAAP EBITDA was $49,191,000 against $17,248,000 a year ago.

Eagle Pharmaceuticals, Inc. to Report Q2, 2017 Results on Aug 09, 2017

Eagle Pharmaceuticals, Inc. announced that they will report Q2, 2017 results at 9:00 AM, Eastern Standard Time on Aug 09, 2017

Eagle Pharmaceuticals, Inc., Q2 2017 Earnings Call, Aug 09, 2017

Eagle Pharmaceuticals, Inc., Q2 2017 Earnings Call, Aug 09, 2017

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Buyback
August 9, 2017
--
Merger/Acquisition
November 11, 2016
Eagle Biologics, Inc.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States
Bertelsmann AG Europe
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Eagle Pharmaceuticals, Inc., please visit www.eagleus.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.